Company news
Photocure Asa (OSL:PHO) news
Photocure Asa news releases on 6ix. Latest, Aug 17, 2026: Photocure Welcomes FDA Proposal to Initiate the Reclassification of Blue Light Cystoscopy Systems…
Press releases & updates
Photocure Welcomes FDA Proposal to Initiate the Reclassification of Blue Light Cystoscopy Systems from Class III to Class II
August 17, 2026
Cost neutrality of BLC versus WLC in a real-world setting demonstrated by new OPTUM study in the U.S.
August 11, 2026
Photocure ASA - Share option grant to members of the board of directors
August 7, 2026
Photocure ASA: Results for the second quarter of 2026
July 29, 2026
Photocure : initiates arbitration in partial milestone payment case with Asieris Pharmaceuticals
July 23, 2026
Photocure ASA - Share option grant
July 14, 2026
Photocure ASA - CFO transition
June 30, 2026
Photocure ASA: Annual general meeting held
June 26, 2026
Photocure ASA to Acquire Vesica Health Inc., Strengthening Leadership in Bladder Cancer Diagnostics
June 4, 2026
AUA 2026: new studies demonstrated Blue Light Cystoscopy benefits in high-risk NMIBC management and cost comparison study
May 18, 2026
Photocure ASA: Results for the first quarter of 2026
May 7, 2026
New health economic methodology published: comparing cost-effectiveness of BLC versus NBI imaging technology in bladder cancer
May 4, 2026
Photocure ASA: Invitation to presentation of first quarter 2026 financial results
April 30, 2026
Photocure ASA: Update on Regulatory Classification for OAY Equipment
April 13, 2026
Photocure: Trials in Progress presented at the European Association of Urology (EAU) 2026 congress aim to enable a more personalized bladder cancer care pathway
March 16, 2026
Asieris: CEVIRA Approved in China as First-in-Class Non-Invasive Therapy for Cervical Precancerous Lesions
March 3, 2026
Photocure partner Asieris announces that EMA has accepted Marketing Authorization Application for CEVIRA in Europe
February 27, 2026
Photocure ASA: Results for the fourth quarter of 2025
February 18, 2026
Photocure ASA: Invitation to presentation of 4th quarter and preliminary full year 2025 financial results
February 11, 2026
The impact of avoiding recurrence: New BRAVO Study abstract at SUO 2025 demonstrates Cost Neutrality in Blue Light versus White Light Cystoscopy comparison
December 8, 2025
New budget impact model study in 4 European countries concludes that BLC use offers a clinically meaningful and economically rational approach to NMIBC management
November 19, 2025
Photocure ASA: Notification of primary insider transaction
October 31, 2025
Photocure ASA: Results for the third quarter of 2025
October 29, 2025
Photocure ASA: Invitation to presentation of third quarter 2025 financial results
October 24, 2025
Photocure and Intelligent Scopes Corporation partner on development of AI for blue light cystoscopy
October 15, 2025
Nokia expands defense portfolio with two advanced tactical communication solutions
September 9, 2025
Photocure ASA: Results for the second quarter of 2025
July 30, 2025
Photocure ASA: Results for the first quarter of 2025
May 8, 2025
Bladder Cancer presentations at AUA2025: Blue Light Cystoscopy improves risk stratification and informed decision making
April 29, 2025